Nanoviricides Inc (NNVC) |
|
5.11 -0.64 (-11.13%)
|
09-23 13:41 |
|
Open: |
5.25 |
Pre. Close: |
5.75 |
|
High:
|
5.4478 |
Low:
|
4.9301 |
|
Volume:
|
1,851,945 |
Market Cap:
|
59M |
|
|
|
|
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 17 full-time employees. The firm is a development-stage company with several drugs in various stages of development. The firm focuses on its research and clinical programs on specific anti-viral therapeutics. The firm is engaged in the application of nanomedicine technologies to the issues of viral diseases. The firm's nanoviricide technology enables direct attacks at multiple points on a virus particle. In addition, the nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.878 - 7.93 |
7.93 - 7.978 |
|
Low:
|
4.621 - 4.662 |
4.662 - 4.699 |
|
Close:
|
6.108 - 6.192 |
6.192 - 6.267 |
|
Technical analysis |
as of: 2021-09-23 1:23:22 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 9.18 One year: 10.72 |
| Support: |
Support1: 5.17 Support2: 3.50 |
| Resistance: |
Resistance1: 7.86 Resistance2: 9.18 |
| Pivot: |
4.33  |
| Moving Average: |
MA(5): 4.77 MA(20): 4.21
MA(100): 4.00 MA(250): 4.06 |
| MACD: |
MACD(12,26): 0.30 Signal(9): 0.12 |
| Stochastic oscillator: |
%K(14,3): 37.03 %D(3): 26.07 |
| RSI: |
RSI(14): 66.83  |
| 52-week: |
High: 8.71 Low: 2.85 Change(%): 50.9 |
| Average Vol(K): |
3-Month: 794748 10-Days: 1568863 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.NNVC has closed It is unclear right now based on current numbers. 186.5% wider than normal. The large width of the bands suggest high volatility as compared to NNVC's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 23 Sep 2021
Should You Buy NanoViricides Inc (NNVC) Stock Thursday Morning? - InvestorsObserver
Wed, 22 Sep 2021
NanoViricides (NNVC) falls 7.11% in Active Trading on September 22 - Equities.com
Wed, 22 Sep 2021
NanoViricides Inc (NNVC) Down 1.45% in Premarket Trading - InvestorsObserver
Wed, 22 Sep 2021
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug - PRNewswire
Tue, 21 Sep 2021
EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile - Benzinga
Tue, 21 Sep 2021
EXCLUSIVE: NanoViricides Highlights 'significant advantages gained by remdesivir encapsulation' Within Its NV-CoV-2 COVID-19 Candidate - Benzinga
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
11 |
| Shares Float (M) |
6 |
|
% Held by Insiders
|
14.97 |
|
% Held by Institutions
|
19.66 |
|
Shares Short (K)
|
634 |
|
Shares Short P. Month (K)
|
689 |
Stock Financials |
|
EPS
|
-3.106 |
|
EPS Est This Year
|
-0.200 |
|
EPS Est Next Year
|
0.040 |
|
Book Value (p.s.)
|
1.870 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-32.6 |
|
Return on Equity (ttm)
|
-102.0 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.716 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-7 |
|
Levered Free Cash Flow (M)
|
-4 |
Stock Valuations |
|
PE Ratio
|
-1.85 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.07 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-9.04 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
